vs

Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

Red Cat Holdings, Inc. is the larger business by last-quarter revenue ($9.6M vs $9.2M, roughly 1.0× Foghorn Therapeutics Inc.). Red Cat Holdings, Inc. runs the higher net margin — -166.0% vs -234.3%, a 68.2% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs 223.8%).

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

FHTX vs RCAT — Head-to-Head

Bigger by revenue
RCAT
RCAT
1.0× larger
RCAT
$9.6M
$9.2M
FHTX
Growing faster (revenue YoY)
RCAT
RCAT
+764.4% gap
RCAT
988.2%
223.8%
FHTX
Higher net margin
RCAT
RCAT
68.2% more per $
RCAT
-166.0%
-234.3%
FHTX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FHTX
FHTX
RCAT
RCAT
Revenue
$9.2M
$9.6M
Net Profit
$-21.7M
$-16.0M
Gross Margin
6.6%
Operating Margin
-258.2%
-181.7%
Net Margin
-234.3%
-166.0%
Revenue YoY
223.8%
988.2%
Net Profit YoY
-11.1%
-29.0%
EPS (diluted)
$-0.35
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FHTX
FHTX
RCAT
RCAT
Q4 25
$9.2M
Q3 25
$8.2M
$9.6M
Q2 25
$7.6M
Q1 25
$6.0M
$1.6M
Q4 24
$2.9M
$0
Q3 24
$7.8M
Q2 24
$6.9M
Q1 24
$5.0M
$5.8M
Net Profit
FHTX
FHTX
RCAT
RCAT
Q4 25
$-21.7M
Q3 25
$-15.8M
$-16.0M
Q2 25
$-17.9M
Q1 25
$-18.8M
$-23.1M
Q4 24
$-19.5M
$-13.3M
Q3 24
$-19.1M
Q2 24
$-23.0M
Q1 24
$-25.0M
$-5.5M
Gross Margin
FHTX
FHTX
RCAT
RCAT
Q4 25
Q3 25
6.6%
Q2 25
Q1 25
-52.2%
Q4 24
Q3 24
Q2 24
Q1 24
18.8%
Operating Margin
FHTX
FHTX
RCAT
RCAT
Q4 25
-258.2%
Q3 25
-226.9%
-181.7%
Q2 25
-279.2%
Q1 25
-385.0%
-765.7%
Q4 24
-840.5%
Q3 24
-305.5%
Q2 24
-386.6%
Q1 24
-558.3%
-76.0%
Net Margin
FHTX
FHTX
RCAT
RCAT
Q4 25
-234.3%
Q3 25
-194.4%
-166.0%
Q2 25
-237.3%
Q1 25
-316.4%
-1418.9%
Q4 24
-682.9%
Q3 24
-244.9%
Q2 24
-333.6%
Q1 24
-495.4%
-93.9%
EPS (diluted)
FHTX
FHTX
RCAT
RCAT
Q4 25
$-0.35
Q3 25
$-0.25
$-0.16
Q2 25
$-0.28
Q1 25
$-0.30
$-0.27
Q4 24
$-0.23
Q3 24
$-0.31
Q2 24
$-0.45
Q1 24
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FHTX
FHTX
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$80.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-108.5M
$253.3M
Total Assets
$198.1M
$286.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FHTX
FHTX
RCAT
RCAT
Q4 25
$80.9M
Q3 25
$89.3M
Q2 25
$72.6M
Q1 25
$61.0M
Q4 24
$55.5M
Q3 24
$57.7M
Q2 24
$138.9M
Q1 24
$79.3M
Stockholders' Equity
FHTX
FHTX
RCAT
RCAT
Q4 25
$-108.5M
Q3 25
$-89.7M
$253.3M
Q2 25
$-76.7M
Q1 25
$-61.7M
$28.9M
Q4 24
$-45.5M
$27.0M
Q3 24
$-28.3M
Q2 24
$-14.3M
Q1 24
$-97.5M
$49.6M
Total Assets
FHTX
FHTX
RCAT
RCAT
Q4 25
$198.1M
Q3 25
$205.0M
$286.0M
Q2 25
$226.2M
Q1 25
$258.7M
$59.7M
Q4 24
$284.0M
$51.1M
Q3 24
$308.4M
Q2 24
$328.6M
Q1 24
$255.0M
$55.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FHTX
FHTX
RCAT
RCAT
Operating Cash FlowLast quarter
$-22.3M
$-23.9M
Free Cash FlowOCF − Capex
$-24.5M
FCF MarginFCF / Revenue
-254.2%
Capex IntensityCapex / Revenue
0.0%
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FHTX
FHTX
RCAT
RCAT
Q4 25
$-22.3M
Q3 25
$-18.9M
$-23.9M
Q2 25
$-21.0M
Q1 25
$-24.0M
$-15.9M
Q4 24
$-24.5M
$-10.1M
Q3 24
$-21.0M
Q2 24
$-25.5M
Q1 24
$-29.3M
$-4.1M
Free Cash Flow
FHTX
FHTX
RCAT
RCAT
Q4 25
Q3 25
$-24.5M
Q2 25
$-21.0M
Q1 25
$-24.0M
$-16.2M
Q4 24
$-25.0M
$-10.2M
Q3 24
$-21.3M
Q2 24
$-25.6M
Q1 24
$-29.4M
$-4.2M
FCF Margin
FHTX
FHTX
RCAT
RCAT
Q4 25
Q3 25
-254.2%
Q2 25
-278.2%
Q1 25
-403.2%
-992.9%
Q4 24
-875.3%
Q3 24
-273.0%
Q2 24
-371.0%
Q1 24
-583.1%
-71.1%
Capex Intensity
FHTX
FHTX
RCAT
RCAT
Q4 25
0.0%
Q3 25
0.0%
6.9%
Q2 25
0.3%
Q1 25
0.5%
16.8%
Q4 24
16.8%
Q3 24
4.0%
Q2 24
0.2%
Q1 24
2.0%
0.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FHTX
FHTX

Segment breakdown not available.

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons